中超控股(002471.SZ):擬5500萬元將中超新材61.11%股權轉讓給中新電材
格隆匯5月22日丨中超控股(002471.SZ)公佈,為調整產業結構以減輕負擔、輕裝前行,江蘇中超控股股份有限公司(以下簡稱“公司”)擬將持有的南京中超新材料股份有限公司(以下簡稱“中超新材”)61.11%的股權以人民幣5500萬元的價格轉讓給江蘇中新電材集團有限公司(以下簡稱“中新電材”)。轉讓完成後,公司將持有中超新材18%股權。
陳友福原為公司控股股東江蘇中超投資集團有限公司(以下簡稱“中超集團”)董事、總經理,現任中超新材董事長、中新電材董事長兼總經理,按照《深圳證券交易所股票上市規則》規定,中新電材為公司的關聯法人,本事項屬於關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.